Idera Pharmaceuticals Inc (IDRA):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10030)
◆英語タイトル:Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10030
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:79
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops DNA and RNA based drug candidates aimed at toll-like receptors (TLR) for the treatment of infectious diseases and for use as vaccine adjuvants. The company initiated a research program employing its gene silencing technologies to suppress the production of proteins associated with diseases by targeting RNA. It designs and formulates proprietary TLR agonists and antagonists to modulate immune responses. The lead products in the pipeline are IMO-2125, IMO-8400, IMO-9200, and antagonists of TLRs 7, 8, and 9 for the treatment of lupus. Idera is headquartered in Massachusetts, the US.

Idera Pharmaceuticals Inc (IDRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Idera Pharma Enters into Agreement with Pillar Partners Foundation 12
Idera Pharma Enters into Research Agreement with University of Texas 13
Licensing Agreements 14
Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15
Equity Offering 16
Idera Pharma Prices Public Offering of Shares for USD50 Million 16
Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 22
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 23
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 25
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 27
Idera Pharmaceuticals Inc – Key Competitors 28
Idera Pharmaceuticals Inc – Key Employees 29
Idera Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 02, 2018: Idera Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 31
May 09, 2018: Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 34
Mar 07, 2018: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 36
Nov 06, 2017: Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 07, 2017: Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results 41
May 04, 2017: Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 44
Mar 15, 2017: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 47
Corporate Communications 50
Sep 18, 2018: Idera Pharmaceuticals names Howard Pien as Board Director 50
Apr 23, 2018: Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors 51
Oct 24, 2017: Idera Pharmaceuticals Provides Corporate Governance Update 52
Apr 18, 2017: Idera Pharmaceuticals Announces Organizational Update 53
Legal and Regulatory 54
Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 54
Product News 55
11/09/2017: Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC) 55
04/11/2017: Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab – for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma 57
02/06/2017: Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development 59
Product Approvals 60
Nov 29, 2017: U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma 60
Jun 22, 2017: Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma 61
Clinical Trials 63
Jun 04, 2018: Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 63
Apr 26, 2018: Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting 65
Apr 17, 2018: Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting 67
Mar 01, 2018: Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) 68
Sep 10, 2017: Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy 69
Sep 08, 2017: Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory 71
Apr 05, 2017: Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting 72
Feb 24, 2017: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 74
Other Significant Developments 75
Jul 16, 2018: Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook 75
Jan 05, 2018: Idera Pharmaceuticals Provides 2018 Update and Outlook 77
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Idera Pharma Enters into Agreement with Pillar Partners Foundation 12
Idera Pharma Enters into Research Agreement with University of Texas 13
Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15
Idera Pharma Prices Public Offering of Shares for USD50 Million 16
Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 22
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 23
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 25
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 27
Idera Pharmaceuticals Inc, Key Competitors 28
Idera Pharmaceuticals Inc, Key Employees 29
Idera Pharmaceuticals Inc, Other Locations 30

List of Figures
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Idera Pharmaceuticals Inc (IDRA):製薬・医療:M&Aディール及び事業提携情報(Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆